Journal: Cell Death & Disease

Article Title: Mitochondrial, metabolic and bioenergetic adaptations drive plasticity of colorectal cancer cells and shape their chemosensitivity

doi: 10.1038/s41419-025-07596-y

Figure Lengend Snippet:

Article Snippet: Irinotecan , Blocks topoisomerase-1 , 2 μM , MedChemExpress , Cat. # HY- 16562.

Techniques: Concentration Assay

Journal: International Journal of Nanomedicine

Article Title: Engineered Cancer Cell Membrane-Functionalized Metal-Organic Frameworks for Irinotecan/Curcumin Codelivery in Colorectal Cancer: Enhanced Efficacy and Mitigated Toxicity

doi: 10.2147/IJN.S558675

Figure Lengend Snippet: MZCC characterization. ( A ) UV−Vis absorbance spectra of ZIF-8, CPT-11, CCM, ZIC and ZICC. ( B ) FT-IR of CCM, CPT-11, ZIF-8, ZIC and ZICC. ( C ) XRD of CCM, ZIF-8, ZIC, ZICC and MZCC. ( D ) TEM image of ZIC, ZICC and MZCC. Scale bar: 100 nm. ( E ) Dynamic light scattering of ZIC, ZICC and MZCC. ( F ) Zeta potentials of ZIC, ZICC and MZCC. ( G ) SDS-PAGE of marker, MCM, ZICC and MZCC.

Article Snippet: Irinotecan was purchased from Aladdin Scientific Co., Ltd. (Shanghai, China).

Techniques: SDS Page, Marker

Journal: International Journal of Molecular Sciences

Article Title: Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells

doi: 10.3390/ijms21186642

Figure Lengend Snippet: IC 50 of irinotecan in NSCLC cells (H1299) and its effects on NF-κB signaling and drug resistance markers. ( A ) When cells were treated with 0–100 μM of irinotecan, the viability (%) decreased in an irinotecan concentration-dependent manner. ( B ) IC 50 of irinotecan was 16.64 μM. ( C ) Western blots of IKKβ, p-IκBα, IκBα, and NF-κB p65 after treatment with 17 μM irinotecan. ( D ) Relative protein expressions of IKKβ, p-IκBα/IκBα, and NF-κB p65 (cytoplasm and nucleus) compared with those before treatment (1.0 fold). ( E ) Changes in drug resistance ( CITED2 , ABCG2 , and CTNNAL1 ) and sensitivity ( BRCA1 ) after irinotecan treatment. # significant difference at each time point after irinotecan treatment ( p < 0.05).

Article Snippet: To determine the IC 50 values of irinotecan (CPT-11; LC Laboratories, Woburn, MA, USA) and LB-100 (Selleckchem, Houston, TX, USA), completely starved H1299 cells were seeded into 96-well plates at 3 × 10 3 cells/well and incubated for 24 h in 10% FBS–RPMI 1640 medium.

Techniques: Concentration Assay, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells

doi: 10.3390/ijms21186642

Figure Lengend Snippet: Inhibition in GWL and ENSA phosphorylation and cyclin B1 level and dephosphorylation of AKT and ERK by the augmentation of PP2A-B55 in GRA16 cells. ( A ) Western blots of PP2A-B55, GWL, p-ENSA, and cyclin B1 expression in cells without irinotecan treatment. ( B ) Relative expression levels of these proteins in vector and GRA16 cells compared with control cells. ( C ) Expression levels of each protein under irinotecan treatment compared with those in ( A ). ( D ) Relative expression levels of these proteins under irinotecan treatment compared with those in ( B ). ( E ) Western blots of p-AKT and p-ERK expression without irinotecan treatment. ( F ) Ratios of p-AKT/AKT and p-ERK/ERK expression without irinotecan treatment. ( G ) Western blots of p-AKT and p-ERK expression under irinotecan treatment. ( H ) Ratios of p-AKT/AKT and p-ERK/ERK expression under irinotecan treatment. * significant at p < 0.05 between control and GRA16 cells; † significant at p < 0.05 between vector and GRA16 cells.

Article Snippet: To determine the IC 50 values of irinotecan (CPT-11; LC Laboratories, Woburn, MA, USA) and LB-100 (Selleckchem, Houston, TX, USA), completely starved H1299 cells were seeded into 96-well plates at 3 × 10 3 cells/well and incubated for 24 h in 10% FBS–RPMI 1640 medium.

Techniques: Inhibition, Phospho-proteomics, De-Phosphorylation Assay, Western Blot, Expressing, Plasmid Preparation, Control

Journal: International Journal of Molecular Sciences

Article Title: Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells

doi: 10.3390/ijms21186642

Figure Lengend Snippet: Effects of GRA16 and irinotecan on the induction of apoptosis and cell cycle arrest in non-small-cell lung carcinoma (NSCLC). Cell viability, cell cycle arrest, and cell apoptosis were investigated in GRA16 cells before and after irinotecan treatment using the CCK-8 assay and FACS analysis. ( A ) Annexin V and propidium iodide (PI) staining without irinotecan treatment. ( B ) Annexin V and PI staining under irinotecan treatment. ( C ) Cell viability and cell count (trypan blue exclusion test) without irinotecan treatment. ( D ) Cell viability and cell count under irinotecan treatment. ( E ) Cell cycle analysis via FACS without irinotecan treatment. ( F ) Cell cycle analysis via FACS under irinotecan treatment. * significant at p < 0.05 between control and GRA16 cells; † significant at p < 0.05 between vector and GRA16 cells.

Article Snippet: To determine the IC 50 values of irinotecan (CPT-11; LC Laboratories, Woburn, MA, USA) and LB-100 (Selleckchem, Houston, TX, USA), completely starved H1299 cells were seeded into 96-well plates at 3 × 10 3 cells/well and incubated for 24 h in 10% FBS–RPMI 1640 medium.

Techniques: CCK-8 Assay, Staining, Cell Counting, Cell Cycle Assay, Control, Plasmid Preparation

Journal: International Journal of Molecular Sciences

Article Title: Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells

doi: 10.3390/ijms21186642

Figure Lengend Snippet: NF-κB inhibition induced by GRA16 in NSCLC regardless of irinotecan treatment. Immunofluorescence assay (IFA) for NF-κB expression in control, vector, and GRA16 cells without ( A ) and with ( B ) irinotecan treatment. BF: bright field, DAPI: nucleus staining. White arrows represent NF-κB p65 protein in the nucleus. Scale bar represents 25 µm. Western blots of IKKβ, p-IκBα, IκBα, and NF-κB p65 without ( C ) and with ( E ) irinotecan treatment and their relative expressions of protein in the cytoplasm and nucleus without ( D ) and with ( F ) irinotecan treatment. Changes in drug resistance ( CITED2 , ABCG2 , and CTNNAL1 ) and sensitivity ( BRCA1 ) markers without ( G ) and with ( H ) irinotecan treatment. Changes in NF-κB target genes related with antiapoptosis ( c-MYC and BCL-2 ) and proapoptosis ( BAX and ARHGEF7 ) markers without ( I ) and with ( J ) irinotecan treatment. * significant at p < 0.05 between control and GRA16 cells; † significant at p < 0.05 between vector and GRA16 cells.

Article Snippet: To determine the IC 50 values of irinotecan (CPT-11; LC Laboratories, Woburn, MA, USA) and LB-100 (Selleckchem, Houston, TX, USA), completely starved H1299 cells were seeded into 96-well plates at 3 × 10 3 cells/well and incubated for 24 h in 10% FBS–RPMI 1640 medium.

Techniques: Inhibition, Immunofluorescence, Expressing, Control, Plasmid Preparation, Staining, Western Blot